Effects of BET Bromodomain Inhibitor JQ1 on Double-Expressor Lymphoma Cell Lines and Its Mechanism.
10.19746/j.cnki.issn.1009-2137.2022.04.018
- Author:
Xue-Yu CHEN
1
;
Xue YAN
2
;
Bin-Yang SONG
1
;
Jian SUN
1
;
Li-Jun MU
1
;
Wei-Ping LI
3
Author Information
1. Department of Hematology, The Second Hospital of Dalian Medical University, Dalian 116027, Liaoning Province, China.
2. Department of Immunology, College of Basic Medical Science, Dalian Medical University, Dalian 116044, Liaoning Province, China.
3. Department of Hematology, The Second Hospital of Dalian Medical University, Dalian 116027, Liaoning Province, China .E-mail: liweiping0910@sina.com.
- Publication Type:Journal Article
- Keywords:
JQ1;
Myc;
double-expressor lymphoma
- MeSH:
Apoptosis;
Azepines/pharmacology*;
Cell Line, Tumor;
Cell Proliferation;
Humans;
Proto-Oncogene Proteins c-myc/metabolism*;
Sincalide/pharmacology*;
Triazoles/pharmacology*;
Xenograft Model Antitumor Assays
- From:
Journal of Experimental Hematology
2022;30(4):1094-1100
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the effects and mechanism of bromodomain and extra-terminal (BET) inhibitor JQ1 on the double-expressor lymphoma (DEL) cell lines.
METHODS:Protein expressions of cMyc and BCL-2 in 3 lymphoma cell lines were checked by Western blot so as to identify DEL cell lines. CCK-8 assay was used to detect the effects of JQ1 on anti-proliferation in the DEL cell lines. Western blot and RT-PCR were used to measure the protein and mRNA expressions of cMyc, BCL-2 and BCL-6 in DEL cell lines which treated by JQ1. Flow cytometry was used to detect the effect of JQ1 on cell apoptosis.
RESULTS:Based on the expressions of cMyc and BCL-2, the SU-DHL6 and OCILY3 cell lines were confirmed as DEL cell lines. CCK-8 assay showed that the proliferation of DEL cell lines was inhibited by JQ1, which was similar to non-DEL cell lines and mainly regulated the expression of cMyc and BCL-6 but not BCL-2. JQ1 had no effects on apoptosis in the DEL cell lines.
CONCLUSION:BET inhibitor JQ1 has anti-tumor effect in the DEL cell lines, thus providing evidence for the therapeutic potential of BET inhibitor JQ1.
